Efficacy of 0.5% Oral Glucose vs Lubricants on Tear Break Up Time in Blepharitis Patients

Main Article Content

Rawaha Awan
Ayesha Zaman
Ammara Atta
Maher Mustansar Ali Qasim
Mahnoor
Shanza Saif Ullah

Abstract

Background: Blepharitis is a chronic inflammatory eyelid disorder associated with tear-film instability and reduced tear breakup time (TBUT), contributing to dry eye symptoms and impaired visual function. While topical lubricants remain the standard treatment for improving tear-film stability, the role of systemic metabolic modulation, such as oral glucose, in influencing TBUT remains unclear. Objective: To evaluate and compare the short-term effects of 0.5% oral glucose solution and lubricant therapy on tear breakup time in patients with mild-to-moderate blepharitis. Methods: A prospective comparative interventional study was conducted on 42 participants aged 18–25 years with clinically diagnosed blepharitis, allocated into two groups: oral glucose (n=21) and lubricant (n=21). Baseline TBUT was measured using fluorescein slit-lamp examination, followed by reassessment at 30 and 120 minutes post-intervention. Statistical analysis was performed using SPSS version 21.0, with independent t-tests applied to compare mean TBUT between groups. Results: Baseline TBUT was comparable between groups (p>0.05). At 30 minutes, the glucose group showed greater improvement, particularly in the left eye (mean difference: 0.87 seconds; p=0.018), with a significant within-group increase (+1.11 seconds; p=0.001). At 120 minutes, TBUT declined in the glucose group but remained higher in the lubricant group, although differences were not statistically significant (p>0.05). Conclusion: Oral 0.5% glucose demonstrated a transient short-term improvement in TBUT, whereas lubricants provided more sustained tear-film stabilization. These findings support lubricants as the primary treatment modality, with oral glucose showing limited adjunctive potential.

Article Details

Section

Articles

How to Cite

1.
Rawaha Awan, Ayesha Zaman, Ammara Atta, Maher Mustansar Ali Qasim, Mahnoor, Shanza Saif Ullah. Efficacy of 0.5% Oral Glucose vs Lubricants on Tear Break Up Time in Blepharitis Patients. JHWCR [Internet]. 2026 Apr. 15 [cited 2026 Apr. 19];4(7):1-11. Available from: https://jhwcr.com/index.php/jhwcr/article/view/1466

References

1. Di Zazzo A, Giannaccare G, Villani E, Barabino S. Uncommon blepharitis. J Clin Med. 2024;13(3):710.

2. Rocha KM, Farid M, Raju L, Beckman K, Ayres BD, Yeu E, et al. Eyelid margin disease (blepharitis and meibomian gland dysfunction): clinical review of evidence-based and emerging treatments. J Cataract Refract Surg. 2024;50(8):876–82.

3. Mason L, Jafri S, Dortonne I, Sheppard JD Jr. Emerging therapies for dry eye disease. Expert Opin Emerg Drugs. 2021;26(4):401–13.

4. Kuo YK, Lin IC, Chien LN, Lin TY, How YT, Chen KH, et al. Dry eye disease: a review of epidemiology in Taiwan, and its clinical treatment and merits. J Clin Med. 2019;8(8):1227.

5. Şimşek C, Doğru M, Kojima T, Tsubota K. Current management and treatment of dry eye disease. Turk J Ophthalmol. 2018;48(6):309–13.

6. Kaštelan S, Gabrić K, Mikuličić M, Mrazovac Zimak D, Karabatić M, Gverović Antunica A. The influence of tear film quality on visual function. Vision (Basel). 2024;8(1):8.

7. Kojima T, Dogru M, Kawashima M, Nakamura S, Tsubota K. Advances in the diagnosis and treatment of dry eye. Prog Retin Eye Res. 2020;78:100842.

8. Rynerson JM, Perry HD. DEBS–a unification theory for dry eye and blepharitis. Clin Ophthalmol. 2016;10:2455–67.

9. Vernhardsdottir RR, Magno MS, Hynnekleiv L, Lagali N, Dartt DA, Vehof J, et al. Antibiotic treatment for dry eye disease related to meibomian gland dysfunction and blepharitis: A review. Ocul Surf. 2022;26:211–21.

10. Kheirkhah A, Kobashi H, Girgis J, Jamali A, Ciolino JB, Hamrah P. A randomized, sham-controlled trial of intraductal meibomian gland probing with or without topical antibiotic/steroid for obstructive meibomian gland dysfunction. Ocul Surf. 2020;18(4):852–6.

11. Hakim FE, Farooq AV. Medical management of blepharitis. In: Blepharitis: A Comprehensive Clinical Guide. Springer; 2021. p. 83–9.

12. Kanclerz P, Bazylczyk N, Radomski SA. Tear film stability in patients with symptoms of dry eye after instillation of dual polymer hydroxypropyl guar/sodium hyaluronate vs single polymer sodium hyaluronate. Int Ophthalmol. 2024;44(1):193.

13. Tsubota K. Short tear film breakup time–type dry eye. Invest Ophthalmol Vis Sci. 2018;59(14):DES64–DES70.

14. Richdale K, Chao C, Hamilton M. Eye care providers’ emerging roles in early detection of diabetes and management of diabetic changes to the ocular surface. BMJ Open Diabetes Res Care. 2020;8(1).

15. Faheem M, Abid S, Naqvi H, Sarfaraz H, ul Abidin F. Frequency of dry eyes with and without posterior blepharitis in diabetes patients. Pak Armed Forces Med J. 2022;72(5):1783–6.

16. Xi L, Qin J, Bao Y. Assessment of tear film optical quality in a young short tear break-up time dry eye: case-control study. Medicine (Baltimore). 2019;98(40):e17255.

17. Pérez-Cano H, Rubalcava-Soberanis M, Salgado RV. Relationship between blepharitis and components of the metabolic syndrome. Arch Soc Esp Oftalmol. 2018;93(10):476–80.

18. Karaca EE, Özek D, Kemer ÖE. Comparison study of two different topical lubricants on tear meniscus and tear osmolarity in dry eye. Cont Lens Anterior Eye. 2020;43(4):373–7.